Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SSKITHRIHWESASLLR
Primary information
sequence IDSeq_7647
Peptide sequenceSSKITHRIHWESASLLR
CancerPDF_ID CancerPDF_ID32, CancerPDF_ID923, CancerPDF_ID1048, CancerPDF_ID1487, CancerPDF_ID2714, CancerPDF_ID8544, CancerPDF_ID9483, CancerPDF_ID9484, CancerPDF_ID9608, CancerPDF_ID12709,
PMID16896061,19795908,16395409,21136997,21136997,23667664,26379225,26379225,21533267,27058005
Protein NameComplement C3f,Complement C3,Complement C3f,Complement C3,Complement C3,Complement C3f,Complement C3,Complement C3,Complement C3,Complement C3
UniprotKB Entry NameCO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN
FluidSerum,Plasma,Serum,Serum,Plasma,Serum,Plasma,Plasma,Serum,Serum
M/Z2021.06,674.36,2021.06,2020.09664,2020.0966,2020.1,2021.1,2037.09,506.03,2021.146
Charge1,3,1,1,1,1,NA,NA,4,NA
Mass (in Da)2021.1,NA,NA,NA,NA,2022.32,NA,NA,NA,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Profiling TechniqueMALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF
Peptide Identification techniqueQ/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,MALDI-TOF/TOF,MALDI-TOF/TOF,LC/MS/MS,LC-MS/MS
Quantification TechniqueNA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,NA,NA,Multiple Reaction Monitoring,NA
Labelled/Label FreeLabel Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free
FDRNA,less than 7%,less than 1 “5,NA,NA,NA,NA,NA,1.49,NA
CancerPDF_ID CancerPDF_ID32, CancerPDF_ID923, CancerPDF_ID1048, CancerPDF_ID1487, CancerPDF_ID2714, CancerPDF_ID8544, CancerPDF_ID9483, CancerPDF_ID9484, CancerPDF_ID9608, CancerPDF_ID12709,
p-Value1.00E-05,NA,less than 0.05,NA,NA,NA,1.00E-04,NA,NA,"0.874,0.404,less than 0.01"
SoftwareMASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT (v 2.3),MASCOT (v 2.3),MASCOT,Proteome Discoverer
Length17,17,17,17,17,17,17,17,17,17
Cancer TypeMetastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Colorectal cancer,Colorectal cancer,Lung adenocarcinoma,Breast cancer
DatabaseNCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,UniprotKB,UniprotKB,Swissprot Database (57.4),SwissProt Database
ModificationNA,NA,NA,NA,NA,NA,NA,Oxidated C3f,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)."
RegulationNA,NA,NA,NA,NA,NA,"Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group.","Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls.","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 1.02 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.19, Upregulated in BC vs healthy with 1.844 fold change"
ValidationIndependent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,NA,NA,MRM-based validation of 19 candidates,NA
Sensitivity95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA,NA,NA
Specificity95% on independent dataset,NA,NA,NA,NA,NA,NA,NA,NA,NA
AccuracyNA,NA,97.5 % on validation dataset,NA,NA,NA,0.9676,NA,NA,NA
Peptide AtlasPeptideAtlas
IEDB533899